DiaTech Holdings, Inc., the premier developer of life science technologies providing treatment directing data to aid physicians in selecting the most appropriate therapy for their patients with cancer, today announced that it has licensed the CEER® Oncology platform from Prometheus Laboratories Inc., a Nestlé Health Science (NHSc) company. The unique CEER immuno-proximity assay configuration delivers industry leading analytical sensitivity and specificity in the identification of potential tumor driver(s) based on a functional proteomic approach, to help guide the selection of the most effective targeted therapy for cancer patients.
The addition of the CEER platform to DiaTech Holdings current MiCK® Assay, a functional drug
response profiling assay, will provide an unprecedented level of patient-centric data on the effectiveness of chemotherapy and targeted therapy treatments, enhancing clinical treatment decision-making and drug development. The company’s strategy is to initiate tumor specific, prospective, randomized, well controlled clinical studies to support regulatory approval of these platforms by the Food and Drug Administration (FDA).
In conjunction with the CEER platform, DiaTech is also announcing that the company will be changing its name to Pierian Biosciences, with offices in Franklin, Tenn., and San Diego, CA. The name change is effective today August 23, 2016. In Greek mythology, the Pierian Spring was considered the metaphorical source of knowledge of art and science and it was believed that drinking from it would deliver tremendous knowledge and inspiration. Moving forward, the company’s intention is to be a source of the broad and deep knowledge necessary to change the cancer treatment experience for providers and patients.
“As oncology moves towards a rationalized treatment approach, our goal is to provide patient specific data to help care teams select the most effective treatment regimens,” says Robert E. Henry, president and chief executive officer of Pierian Biosciences. “In light of value-based care, there is a sense of urgency to provide physicians with more biologically relevant tumor profiling to optimize care for their patients. Combined, MiCK and CEER offer expansive actionable information on cancer treatment effectiveness.” According to Henry, “We will provide clarity to oncologists in terms of actionable, treatment directing data to support better outcomes and lower costs”.
“We are delighted that DiaTech Holdings will take CEER Oncology forward and share their commitment to personalized medicine”, says Cathy Kerzner, chief executive officer of Prometheus.
You can read the original Press Release on Perianbio’s website.